摘要
目的:探究为晚期非小细胞肺癌患者采用化疗联合贝伐单抗进行治疗的临床效果。方法:选择2019年1月至2021年1月射阳县人民医院接诊的晚期非小细胞肺癌患者80例进行分组研究。根据治疗方案的不同将其分为常规化疗组和贝伐单抗组(40例/组)。对常规化疗组患者进行常规化疗,在此基础上为贝伐单抗组患者采用贝伐单抗进行治疗。然后比较两组患者的临床疗效和不良反应的发生率。结果:贝伐单抗组患者治疗的总有效率(90.00%)高于常规化疗组患者治疗的总有效率(72.50%),P<0.05。治疗后,贝伐单抗组患者不良反应的发生率(10.00%)与常规化疗组患者不良反应的发生率(7.50%)相比,P>0.05。结论:与采用单纯化疗相比,为晚期非小细胞肺癌患者采用化疗联合贝伐单抗进行治疗的效果较好,且安全性较高。
Objective:To explore the clinical effect of chemotherapy combined with bevacizumab in patients with advanced non-small cell lung cancer.Methods:A total of 80 patients with advanced NSCLC treated in Sheyang County People’s Hospital from January 2019 to January 2021 were selected and divided into groups.According to different treatment regimens,they were divided into conventional chemotherapy group and bevacizumab gr oup(40 cases/group).Patients in the conventional chemotherapy group were treated with conventional chemotherapy,and on this basis,patients in the bevacizumab group were treated with bevacizumab.Then the clinical efficacy and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of bevacizumab group(90.00%)was higher than that of conventional chemotherapy group(72.50%),P<0.05.After treatment,the incidence of adverse reactions in bevacizumab group(10.00%)was compared with that in conventional chemotherapy group(7.50%),P>0.05.Conclusion:Compared with chemotherapy alone,chemotherapy combined with bevacizumab has better efficacy and higher safety in patients w ith advanced NSCLC.
作者
金兴涛
JIN Xingtao(Department of Oncology,Sheyang People’s Hospital,Yancheng City,Jiangs u Province,Sheyang 224300)
关键词
非小细胞肺癌
化疗
贝伐单抗
Non-small cell lung cancer
Chemotherapy
bevacizumab
